High‐dose cyclophosphamide for hard‐to‐treat patients with relapsed or refractory B‐cell non‐Hodgkin's lymphoma, a phase II result-Reference-Cited by-同舟云学术

High‐dose cyclophosphamide for hard‐to‐treat patients with relapsed or refractory B‐cell non‐Hodgkin's lymphoma, a phase II result

Published:2020-01-28 Issue:4 Volume:104 Page:281-290
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Michot Jean‐Marie¹²^ORCID,Annereau Maxime³,Danu Alina²,Legoupil Clémence³⁴,Bertin Louis³,Chahine Claude²,Achab Nadia³,Antosikova Anna²,Cerutti Ariane³,Rossignol Julien²,Ghez David²,Willekens Christophe²,Dartigues Peggy⁵,Lazarovici Julien²,Lemare Francois³,Ribrag Vincent¹²

Affiliation:

1. Département des Innovations Thérapeutiques et Essais Précoces Gustave Roussy Université Paris‐Saclay Villejuif France

2. Département d'Hématologie Gustave Roussy Université Paris‐Saclay Villejuif France

3. Pharmacy Gustave Roussy Université Paris‐Saclay Villejuif France

4. Oncostat INSERM U1018 Centre de recherche en épidémiologie et santé des populations Université Paris‐SudUniversité Paris‐Saclay Villejuif France

5. Département de Pathologie Gustave RoussyUniversité Paris‐Saclay Villejuif France

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13369

Reference37 articles.

1. High dose cyclophosphamide therapy in solid tumors: Therapeutic, toxic, and immunosuppressive effects

2. High-dose cyclophosphamide in the treatment of refractory lymphomas and solid tumor malignancies

3. High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma

4. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma.

5. Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Car T Cells in Solid Tumors: Overcoming Obstacles;International Journal of Molecular Sciences;2024-04-10

2. Upregulation of Nrf2/HO-1 Signaling and Attenuation of Oxidative Stress, Inflammation, and Cell Death Mediate the Protective Effect of Apigenin against Cyclophosphamide Hepatotoxicity;Metabolites;2022-07-14

3. A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies;Stem Cell Research & Therapy;2021-07-28

4. The outcome of relapsed/refractory hodgkin's lymphoma patients post autologous bone marrow transplantation in a Baghdad Medical City Complex Center;Iraqi Journal of Hematology;2021